CompletedPhase 4Results posted

Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes

Lead sponsor

University of Miami

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

100

Study population

Obesity / overweight, Type 2 diabetes

Eligibility highlights

•BMI ≥27•HbA1c ≤8%

Primary endpoint

•Visceral fat, change

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02014740

Org study ID20120811

Timeline

Milestones

Study first posted2013-12-18estimated

Results first posted2018-03-22actual

Last update posted2019-06-06actual

Study start2014-03 (month precision)

Primary completion2017-03actual (month precision)

Study completion2017-03actual (month precision)

Assets

Investigational agents

Liraglutide

Who this study enrolls

Obesity / overweightType 2 diabetes

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Type 2 diabetes, as defined by ADA criteria

•HbA1c < 8% measured at least 1 month prior to this study

•BMI ≥27 kg/m2

•Pre-treatment with Metformin

•Age > 18 and < 65 years old

Exclusion criteria

•• Known contra-indications to Liraglutide, such as previous history of pancreatitis or medullary thyroid carcinoma, personal or family history of MEN, in accordance with risks and safety information included in the latest updated Prescribing Information for Victoza®

-Type 1 diabetes, as defined by American Diabetes Association (ADA) criteria

-Insulin dependent or treated type 2 diabetes

-Current use of other injectable incretins

-History of diabetes ketoacidosis

-Advanced Chronic Kidney Disease, as defined by Glomerular Filtration Rate (GFR) < 30 mL/min/1.73m2

-Clinical signs or symptoms of New York Heart Association (NYHA) class III-IV heart failure

-Clinical or laboratory evidences of chronic active liver diseases

-Acute or chronic infective diseases

-Cancer or chemotherapy

-Current use of systemic corticosteroids or in the 3 months prior this study

-Known or suspected allergy to Liraglutide, excipients, or related products

-Pregnant, breast-feeding or the intention of becoming pregnant

-Females of childbearing potential who are not using adequate contraceptive methods

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

2 endpoints

Primary/registry result

Echocardiographic Epicardial Fat Thickness

Time frame:6 months

Visceral fat, change

change from baseline, improvement

Posted result

Group	Mean · mm	95% CI
LiraglutideBaseline	9.6	-
3-month	6.8	-
6-month	6.2	-
MetforminBaseline	7.4	-
3-month	7.5	-
6-month	6.9	-

Primary/protocol endpoint

Echocardiographic Epicardial Fat Thickness

Time frame:6 months

Visceral fat, change

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Liraglutide causes large and rapid epicardial fat reduction.
Obesity (Silver Spring, Md.)2017 Feb (month)PMID28124506doi:10.1002/oby.21718via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.